

## Forum Review

# H<sub>2</sub>O<sub>2</sub> Signaling in the Nigrostriatal Dopamine Pathway via ATP-Sensitive Potassium Channels: Issues and Answers

MARAT V. AVSHALUMOV, LI BAO, JYOTI C. PATEL, and MARGARET E. RICE

### ABSTRACT

The role of reactive oxygen species (ROS) as signaling agents is increasingly appreciated. Studies of ROS functions in the central nervous system, however, are only in their infancy. Using fast-scan cyclic voltammetry and fluorescence imaging in brain slices, the authors discovered that hydrogen peroxide (H<sub>2</sub>O<sub>2</sub>) is an endogenous regulator of dopamine release in the dorsal striatum. Given the key role of dopamine in motor, reward, and cognitive pathways, regulation by H<sub>2</sub>O<sub>2</sub> has implications for normal dopamine function, as well as for dysfunction of dopamine transmission. In this review, data are summarized to show that H<sub>2</sub>O<sub>2</sub> is a diffusible messenger in the striatum, generated downstream from glutamate receptor activation, and an intracellular signal in dopamine neurons of the substantia nigra, generated during normal pacemaker activity. The mechanism by which H<sub>2</sub>O<sub>2</sub> inhibits dopamine release and dopamine cell activity is activation of ATP-sensitive K<sup>+</sup> (K<sub>ATP</sub>) channels. Characteristics of the neuronal and glial antioxidant networks required to permit H<sub>2</sub>O<sub>2</sub> signaling, yet prevent oxidative damage, are also considered. Lastly, estimates of physiological H<sub>2</sub>O<sub>2</sub> levels are discussed, and strengths and limitations of currently available methods for H<sub>2</sub>O<sub>2</sub> detection, including fluorescence imaging using dichlorofluorescein (DCF) and the next generation of fluorescent probes, are considered.

*Antioxid. Redox Signal.* 9, 219–231.

### INTRODUCTION

**R**EACTIVE OXYGEN SPECIES (ROS) are often considered to be toxic 'byproducts' of cell metabolism. Indeed, increased ROS production and oxidative stress contribute in cell death following acute brain injury, including cerebral ischemia–reperfusion (29, 34, 74, 127), as well as in slowly progressing neurodegenerative disorders such as Parkinson's disease (57, 97, 144). This view of ROS is evolving rapidly, however, in light of increasing evidence that ROS can also act as cellular messengers that target physiological processes from short-term ion channel activation (11, 14, 75, 132) and regulation of cell phosphorylation pathways (78, 110, 128) to gene transcription (58, 67). Hydrogen peroxide (H<sub>2</sub>O<sub>2</sub>) is a particularly intriguing candidate as a signaling molecule because it is neutral and membrane permeable (107) and can

therefore diffuse freely from a site of generation, as does the established diffusible messenger, nitric oxide (NO<sup>•</sup>). Moreover, H<sub>2</sub>O<sub>2</sub> has no unpaired electrons and is therefore not a free radical, in contrast to superoxide (•O<sub>2</sub><sup>−</sup>), the hydroxyl radical (•OH), and even NO<sup>•</sup>, and so does not readily cause oxidative damage (43).

Research in our laboratory over the past decade has focused on two primary topics. The first is the neuroprotective role of low molecular weight antioxidants, including ascorbate; the second is regulation of dopamine (DA) release by endogenous neurotransmitters and neuromodulators. These topics converged when we began to examine DA release regulation under conditions of oxidative stress.

Dopaminergic transmission is important in a wide range of brain functions, including learning and cognition (32), control of movement (3, 30, 59), and mediation of desire and re-

ward (27). Consequently, *dysfunction* of dopaminergic transmission has been implicated in several significant brain disorders, including the psychoses of schizophrenia, the movement deficits of Parkinson's disease, and addiction to substances including cocaine and amphetamine. Our recent discovery that endogenously generated  $H_2O_2$  regulates DA transmission in the nigrostriatal pathway via activation of ATP-sensitive potassium ( $K_{ATP}$ ) channels, therefore, has implications for both normal and pathophysiological conditions. Our evidence thus far suggests that  $K_{ATP}$ -channel opening in DA neurons is a direct effect of  $H_2O_2$  (14), consistent with findings from previous electrophysiological studies of the effect of  $H_2O_2$  at  $K_{ATP}$  channels in isolated membrane patches from cardiac myocytes (75,132). This contrasts sharply with previously recognized mechanisms of  $H_2O_2$  signaling that involve intracellular signaling cascades (for review, see Refs. 78, 110, 128).

In this review, we summarize our recent studies showing that  $H_2O_2$  is a diffusible and intracellular messenger in the nigrostriatal DA pathway. We will then discuss characteristics of the neuronal and glia antioxidant networks that permit  $H_2O_2$  signaling, yet prevent oxidative damage. Lastly, we will consider several methodological issues inherent in the examination of  $H_2O_2$  as a neuromodulator, including estimates of physiologically relevant concentrations of  $H_2O_2$  and characteristics of available and emerging fluorescent dyes for  $H_2O_2$  imaging. Together, the studies presented illustrate how the use of a combination of methods, including voltammetric detection of DA release, whole-cell recording, and ROS imaging in brain slices, together with pharmacological manipulation of tissue peroxidase activity, can provide new insights into the roles of  $H_2O_2$  in the CNS.

Most experimental data presented were obtained *in vitro* using brain slices. Brain slice preparations offer three main advantages for the kinds of questions we have addressed. First, local brain microcircuitry, including synaptic connections and neuron–glial interactions (13), is preserved in slices. Second, the three-dimensional cytoarchitecture of the tissue is maintained, so that normal intra- and extracellular compartments are intact (112). Third, the use of *in vitro* slices facilitates accurate electrode placement, ease of combining imaging methods with other techniques, and ready application of pharmacological agents at known concentrations. Reflecting these advantages, a number of mechanistic insights into the regulation of DA release have been obtained using brain slices, which allow voltammetric detection of DA release in discrete brain regions, without complicating factors inherent to *in vivo* studies, including animal behavior, anesthesia, and indirect effects from distant structures via long pathways (for review, see Ref. 101).

## $H_2O_2$ AS A SIGNALING AGENT IN THE NIGROSTRIATAL PATHWAY

Generation of ROS occurs during a variety of metabolic processes, the most important of which is mitochondrial respiration, which produces  $\cdot O_2^-$  from a single-electron reduction of molecular oxygen (25, 89, 106). Additional sources of ROS

include enzymes such as monoamine oxidase, which produced  $H_2O_2$  during deamination of DA and other monoamines (43, 116), and NADPH oxidase (117, 120), which produce  $\cdot O_2^-$  that can participate in various signaling cascades. Levels of  $\cdot O_2^-$  are managed by mitochondrial and cytosolic forms of superoxide dismutase; dismutation of  $\cdot O_2^-$  produces  $H_2O_2$  that is regulated by glutathione (GSH) peroxidase, which is found in mitochondria and in the cytosol, and by catalase, which is localized in peroxisomes (42, 52, 129). Interaction of either  $\cdot O_2^-$  or  $H_2O_2$  with trace metal ions, including iron and copper, can produce the aggressive radical,  $\cdot OH$ , which is neutralized primarily by the low molecular weight antioxidants GSH and ascorbate (42). Thus, both enzymes and low molecular weight antioxidants work together to regulate ROS and prevent oxidative damage. A role for  $H_2O_2$  and other ROS as neuromodulators requires that oxidant regulation must be more subtle than previously thought, however.

Our initial studies of the effect of  $H_2O_2$  on neurotransmission were based on previous work by Terry Pellmar (103–105), who had shown that exogenous  $H_2O_2$  could suppress the amplitude of evoked population spikes in guinea pig hippocampal slices, possibly by inhibiting transmitter release. We tested the effect of  $H_2O_2$  on transmitter release directly in guinea pig striatal slices using real-time monitoring of evoked extracellular DA concentration ( $[DA]_o$ ) with carbon-fiber microelectrodes and fast-scan cyclic voltammetry. Consistent with Pellmar's hypothesis, exogenous  $H_2O_2$  (1.5 mM, 15 min) causes a reversible 30–40% decrease in pulse-train evoked  $[DA]_o$  that is not accompanied by loss of tissue DA content or evidence of oxidative damage (38). It should also be noted that 1.2 mM  $H_2O_2$  has no effect, demonstrating the marked efficacy of brain slice preparations in handling excess  $H_2O_2$  (see also Ref. 13).


In the course of our experiments, we also obtained data suggesting that *endogenous*  $H_2O_2$  might have a physiologically relevant role in the regulation of axonal DA release in striatum. These findings shifted our focus from viewing  $H_2O_2$  as a mediator of oxidative stress, to viewing it as a neuromodulator. We explored the potential modulatory role for endogenously generated  $H_2O_2$  by manipulating slice peroxidase activity (12, 38, 39). Amplification of endogenous  $H_2O_2$  levels by inhibiting GSH peroxidase with mercaptosuccinate (MCS) also causes a 30–40% decrease in pulse-train evoked  $[DA]_o$  in dorsolateral striatum similar to that seen with exogenously applied  $H_2O_2$  (12, 39). Again, no change in DA content is seen and DA release suppression is fully reversible after MCS washout or when the slice is superfused with catalase in the continued presence of MCS (12). Similar suppression of evoked  $[DA]_o$  is seen in the presence of MCS in the shell of the nucleus accumbens and in the substantia nigra pars compacta (SNc), consistent with a modulatory role for  $H_2O_2$  in those regions, as well (39).

### *Modulatory $H_2O_2$ in striatum is generated downstream from glutamatergic AMPARs*

Importantly, further studies showed that MCS has no effect on  $[DA]_o$  evoked by a single stimulus pulse (12), implying that modulatory  $H_2O_2$  is generated *dynamically* during the

initial pulse(s) of a train, then inhibits DA release during subsequent pulses. This dynamic regulation is rapid, with DA release suppression seen within a few hundred milliseconds after initiation of a 10 Hz pulse train (12). The requirement for multiple-pulse stimulation also implied the involvement of striatal circuitry. Given that previous studies in cultured neurons had shown that glutamate receptor activation can enhance mitochondrial H<sub>2</sub>O<sub>2</sub> generation (23, 31, 55, 109), we reasoned that locally evoked glutamate release from the corticostriatal pathway might contribute to generation of modulatory H<sub>2</sub>O<sub>2</sub>. Consistent with normal glutamate-dependent suppression of striatal DA release, blockade of glutamatergic AMPA receptors (AMPA) by the selective antagonist, GYKI-52466 causes up to a 100% increase in evoked [DA]<sub>o</sub> versus control (11, 12) (Fig. 1A). Additionally, the apparent absence of presynaptic ionotropic glutamate receptors on DA terminals (22, 40) suggests that any glutamatergic influence must be indirect. The involvement of a diffusible inhibitory intermediate like H<sub>2</sub>O<sub>2</sub> would provide a link between glutamatergic and dopaminergic synapses in the absence of direct synaptic contact.

The central role of H<sub>2</sub>O<sub>2</sub> in AMPAR-dependent inhibition of DA release was demonstrated by the complete prevention of the effect of AMPAR blockade in the presence of exogenous catalase (Fig. 1B) or GSH peroxidase (12). Is AMPAR-dependent H<sub>2</sub>O<sub>2</sub> generation the primary source of modulatory H<sub>2</sub>O<sub>2</sub> in the striatum? The answer appears to be yes because the usual suppression of evoked [DA]<sub>o</sub> when GSH peroxidase is inhibited by MCS is abolished when AMPARs are blocked by GYKI-52466 (12).



**FIG. 1. Regulation of striatal DA release by glutamate and GABA requires H<sub>2</sub>O<sub>2</sub>.** (A) AMPAR blockade by GYKI-52466 (GYKI; 50  $\mu$ M) causes a ~100% increase in evoked [DA]<sub>o</sub> in striatum ( $p < 0.001$ ,  $n = 6$ ). (B) The effect of AMPAR blockade is prevented by catalase (Cat, 500 U/mL). (C) GABA<sub>A</sub> receptor blockade by picrotoxin (PTX; 100  $\mu$ M) causes a ~50% decrease in evoked [DA]<sub>o</sub> ( $p < 0.001$ ,  $n = 6$ ). (D) Catalase abolishes the effect of picrotoxin. Responses in the presence of heat-inactivated catalase were the same as control. Data are means  $\pm$  SEM, illustrated as percentage of same-site control (modified from Ref. 12).

Interestingly, GABA-dependent regulation of DA release in dorsal striatum also involves modulatory H<sub>2</sub>O<sub>2</sub>. Under control conditions, blockade of GABA<sub>A</sub> receptors (GABA<sub>A</sub>Rs) by picrotoxin causes a ~50% decrease in evoked [DA]<sub>o</sub>, indicating that GABA<sub>A</sub>R activation normally *enhances* DA release (Fig. 1C). The influence of GABA on DA release, like that of glutamate, must be indirect, since DA axons also do not express GABA<sub>A</sub>Rs (63). Importantly, the effect of picrotoxin is completely prevented by catalase (Fig. 1D), implicating H<sub>2</sub>O<sub>2</sub> in this process. Moreover, GABA<sub>A</sub>R blockade has no effect when AMPARs are blocked. Together, these data indicate that glutamate and GABA act on the same pool of modulatory H<sub>2</sub>O<sub>2</sub> that is generated downstream from AMPARs.

### *K<sub>ATP</sub> channels mediate H<sub>2</sub>O<sub>2</sub>-dependent inhibition of striatal DA release*

The findings discussed thus far show that endogenous H<sub>2</sub>O<sub>2</sub> is an inhibitory messenger that mediates the effects of glutamate and GABA on axonal DA release in dorsal striatum. How does H<sub>2</sub>O<sub>2</sub> inhibit DA release? The answer is that H<sub>2</sub>O<sub>2</sub> generation leads to the opening of K<sub>ATP</sub> channels (11, 12, 14). Previous physiological studies demonstrated that *exogenous* H<sub>2</sub>O<sub>2</sub> can cause membrane hyperpolarization and decreased excitation by activating a K<sup>+</sup> conductance in a variety of cell types, including hippocampal CA1 neurons, cardiac myocytes, and pancreatic  $\beta$ -cells (84, 75, 122, 132). Our studies of DA release in striatal slices provided the first evidence that endogenous H<sub>2</sub>O<sub>2</sub> causes *functionally relevant* activation of K<sub>ATP</sub> channels. Blockade of K<sub>ATP</sub> channels with either tolbutamide or glibenclamide causes a significant increase in [DA]<sub>o</sub> versus control during local pulse-train stimulation, indicating that K<sub>ATP</sub> channels are activated under these conditions and that these channels inhibit DA release (11, 12). Blockade of K<sub>ATP</sub> channels also prevents the inhibitory effect of MCS on DA release, as well as the usual effects of AMPAR blockade by GYKI-52466 and GABA<sub>A</sub>R blockade by picrotoxin, confirming that K<sub>ATP</sub> channels are *required* for modulation of DA release by H<sub>2</sub>O<sub>2</sub>, glutamate, and GABA.

We then examined which subtype of K<sub>ATP</sub> channels mediates H<sub>2</sub>O<sub>2</sub> sensitivity. These channels are octameric proteins composed of four inwardly rectifying pore-forming units, typically Kir6.2 in neurons (7, 79), and four sulfonylurea receptor sites (SUR1 or SUR2) (2). SUR1- and SUR2-based channels can be distinguished by their differential sensitivity to K<sub>ATP</sub>-channel openers, with diazoxide preferentially acting at SUR1-based channels and cromakalim at SUR2-based channels (15, 76). In dorsal striatum, K<sub>ATP</sub> channel opening by either diazoxide or cromakalim causes a 30–40% suppression of DA release; however, SUR1-selective diazoxide prevents the usual pattern of H<sub>2</sub>O<sub>2</sub>-dependent modulation by MCS, GYKI-52466, and picrotoxin, whereas these effects persist in the presence of SUR2-selective cromakalim (11). These data imply that when SUR1-based K<sub>ATP</sub> channels have already been opened by diazoxide, this occludes normal K<sub>ATP</sub>-channel dependent modulation by H<sub>2</sub>O<sub>2</sub>.

### Modulatory $H_2O_2$ in striatum is generated in medium spiny neurons

Increasing evidence implicates medium spiny neurons as the primary cellular source of modulatory  $H_2O_2$  in dorsal striatum. Not only are these the most abundant striatal neurons (90–95%) (80), but they also express both AMPARs and GABA<sub>A</sub>Rs, in contrast to DA axons in dorsal striatum, which apparently express neither (22, 40, 63). Recent fluorescence imaging studies in our laboratory support the hypothesis that medium spiny neurons are a key cellular source of modulatory  $H_2O_2$  in dorsal striatum (102). In these studies, dihydrodichlorofluorescein ( $H_2DCF$ ) diacetate (7  $\mu M$ ) was loaded into individual medium spiny neurons via the patch pipette used for simultaneous whole-cell recording (for methods, see Refs. 14 and 19). Cleavage of the diacetate group by intracellular esterases leaves  $H_2DCF$  trapped in the cell for subsequent oxidation to fluorescent DCF. Basal DCF fluorescence is seen in all striatal spiny neurons, reflecting a tonic level of  $H_2O_2$  and other ROS (19). Local stimulation (with the same 30 pulse, 10 Hz pulse trains that we typically use to elicit concurrent release of DA and glutamate) causes a ~30% increase in DCF fluorescence in these cells, which is further enhanced when GSH peroxidase is inhibited by MCS. Strikingly, AMPAR blockade by GYKI-52466 prevents this stimulus-activated  $H_2O_2$  generation in medium spiny neurons, confirming glutamate-dependent  $H_2O_2$  generation (102).


Our working model of axonal DA release regulation by glutamate, therefore, is that  $H_2O_2$  is generated in the dendrites of medium spiny neurons after glutamate release and AMPAR activation. Modulatory  $H_2O_2$  then diffuses to adjacent DA synapses, where it inhibits DA release via opening of SUR1-containing  $K_{ATP}$ -channels. By decreasing dendritic excitability, GABA acting via GABA<sub>A</sub>Rs lessens  $H_2O_2$  production in medium spiny neurons; conversely, when GABA<sub>A</sub>Rs are blocked, activity-dependent  $H_2O_2$  production would be increased, leading to greater suppression of DA release. By contrast, when AMPARs are blocked,  $H_2O_2$  generation is minimal, DA release increases, and GABA<sub>A</sub>R-dependent regulation is lost (12).

### Endogenous $H_2O_2$ acts via $K_{ATP}$ channels to regulate DA neuron excitability in SNc

Consistent with the abundant expression of  $K_{ATP}$  channels throughout the nigrostriatal pathway (56, 95, 138), the activity of DA neurons in the SNc is also regulated by  $H_2O_2$  acting via  $K_{ATP}$  channels (14). Both basal and elevated  $H_2O_2$  levels have significant effects on DA cell membrane properties. In midbrain slice preparations, DA neurons exhibit spontaneous pacemaker activity. Under these conditions, basal DCF fluorescence is readily detected in DA neurons loaded with  $H_2DCF$  diacetate, consistent with tonic  $H_2O_2$  generation in these cells (14). Strikingly, this basal  $H_2O_2$  tone has a significant effect on DA cell excitability: depletion of intracellular  $H_2O_2$  by including catalase in the patch-pipette or blockade of  $K_{ATP}$  channels by glibenclamide causes a ~40% increase in spontaneous firing rate in all DA neurons tested (Fig. 2). Moreover, catalase has no effect in cells patched in the pres-


ence of glibenclamide (Fig. 2). Importantly, the backfill solution in these studies contained 3 mM ATP, at which concentration  $K_{ATP}$  channels should be closed (70). Thus, it is unlikely that the resting  $K_{ATP}$  channel tone in DA neurons is caused by low ATP. Indeed, previous studies using inside-out membrane patches from cardiac cells suggest that  $H_2O_2$  can have a direct effect on  $K_{ATP}$ -channel opening by decreasing channel sensitivity to ATP (75, 132). This is likely to involve one or more redox-sensitive sites, although it should be noted that sulfhydryl complexing agents cause channel closure, rather than opening (41).

In companion studies using DCF fluorescence to visualize intracellular  $H_2O_2$ , we found that moderate increases in  $H_2O_2$  ( $\leq 25\%$  increase in fluorescence intensity) during partial inhibition of GSH peroxidase by MCS (0.1–0.3 mM) (Fig. 3) has no effect on DA neuron firing rate. However, with greater GSH peroxidase inhibition (1 mM MCS) or application of exogenous  $H_2O_2$  (1.5 mM), 50% of recorded cells, ‘responders’, show  $K_{ATP}$ -channel dependent hyperpolarization, whereas 50%, ‘nonresponders’, do not (14). This distribution is similar to that of metabolically sensitive and insensitive DA neurons reported previously by Liss *et al.* (88), in which greater metabolic sensitivity was found to be mediated by SUR1-based  $K_{ATP}$  channels. Indeed, we found that  $H_2O_2$ -responders also hyperpolarize with SUR1-selective diazoxide, but not with SUR2-selective cromakalim, showing that SUR1 expression conveys sensitivity to elevated  $H_2O_2$  (14), as described above for striatum. When endogenous  $H_2O_2$  levels are increased by inhibiting the predominant peroxidase in SNc (72), catalase, with 3-aminotriazole (ATZ), however, all DA neurons respond with glibenclamide-reversible hyperpolarization. DCF imaging data indicates that ATZ rapidly amplifies intracellular  $H_2O_2$ , whereas MCS causes a slower in-



**FIG. 2. Regulation of spontaneous activity in DA neurons by  $H_2O_2$  and  $K_{ATP}$  channels.** Pacemaker activity in DA neurons in the SNc increases progressively when catalase (Cat; 500 U/mL) included in the patch-pipette backfill solution ( $n = 7$ ); heat-inactivated catalase (I-Cat) does not alter spontaneous activity ( $n = 6$ ). Blockade of  $K_{ATP}$  channels with glibenclamide (Glib, 100 nM) 15 min before patching increases firing rate ( $n = 5$ ;  $p < 0.01$ ) and prevents the Cat-induced increases in firing rate ( $n = 5$ ). Data are means  $\pm$  SEM; \*\* $p < 0.01$  and \*\*\* $p < 0.001$  vs. control frequency after 10 min recording (modified from Ref. 14).





**FIG. 3. Concentration-dependent effect of GSH peroxidase inhibition by MCS on H<sub>2</sub>O<sub>2</sub> amplification.** Inhibition of GSH peroxidase by MCS (0.1–1 mM) causes a progressive increase in DCF fluorescence intensity (FI), indicating increasing H<sub>2</sub>O<sub>2</sub> levels ( $R^2 = 0.946$ ). All concentrations were tested in each cell ( $n = 7$ ;  $***p < 0.001$  vs. basal). Images are representative examples of DCF fluorescence for each concentration of MCS tested in a single DA neuron (scale bars = 20  $\mu$ m) (modified from Ref. 14, including conversion of images to grayscale).

crease (14). Thus, SUR2-based  $K_{ATP}$  channels can also be activated by sufficiently *high* and/or *rapid* increases in H<sub>2</sub>O<sub>2</sub>. Overall, these data show that H<sub>2</sub>O<sub>2</sub> serves an autoregulatory role in SNc DA neurons, in which activity-dependent H<sub>2</sub>O<sub>2</sub> generation leads to suppression of neuronal activity via  $K_{ATP}$  channels, thus enhancing the reciprocal relationship between metabolism and excitability.

### TRUE AND FALSE SIGNALING BY MITOCHONDRIAL H<sub>2</sub>O<sub>2</sub> IN THE STRIATUM

#### *Dynamic H<sub>2</sub>O<sub>2</sub> signaling originates in mitochondria*

We have examined three possible subcellular sources of H<sub>2</sub>O<sub>2</sub> that might contribute to dynamic, glutamate-dependent regulation of axonal DA release in dorsal striatum (18). The first is mitochondrial respiration. Of the four mitochondrial complexes, complexes I and III are the primary sources of  $\cdot O_2^-$  and H<sub>2</sub>O<sub>2</sub> during O<sub>2</sub> consumption (1, 35, 85). The second potential source of H<sub>2</sub>O<sub>2</sub> is monoamine oxidase (MAO), which catalyzes DA deamination via a two-electron reduction of O<sub>2</sub> to H<sub>2</sub>O<sub>2</sub> (43, 116). There are two isoforms MAO, type A (MAO-A) and type B (MAO-B); DA is a good substrate for both (123). The third possible source of H<sub>2</sub>O<sub>2</sub> is NADPH oxidase, a family of membrane-associated, multi-subunit enzymes that catalyze the one-electron reduction of O<sub>2</sub> to form  $\cdot O_2^-$  and H<sub>2</sub>O<sub>2</sub> (16, 17). In the CNS, NADPH oxidase is expressed predominately in microglial cells and to a lesser extent in neurons (143), including the recent identification of a functional form in hippocampal synapses (131).

To evaluate the role of mitochondria in dynamic generation of modulatory H<sub>2</sub>O<sub>2</sub>, we used a cocktail of rotenone (50 nM), a complex I inhibitor, and succinate (5 mM), a mitochondrial complex II substrate, which should limit H<sub>2</sub>O<sub>2</sub> production, but maintain tissue ATP levels (18). Although slice ATP content falls after 90 min in rotenone alone, companion slices in the rotenone-succinate cocktail show no drop in ATP, validating our rationale for the use of this cocktail. Strikingly, the effects of both GYKI-52466 and MCS on evoked [DA]<sub>o</sub> is lost in the presence of the rotenone-succinate cocktail, implicating mitochondrial complex I as the primary source of modulatory H<sub>2</sub>O<sub>2</sub> in the striatum (18). By contrast, the effect of MCS on evoked [DA]<sub>o</sub> is unaffected by either a cocktail of MAO inhibitors, clorgyline (MAO-A) and pargyline (MAO-B), or an NADPH oxidase inhibitor, phenylarsine oxide. It should be noted that our choice of NADPH oxidase inhibitors was limited to phenylarsine oxide, because it was the only one of several inhibitors examined that did not interfere with voltammetric detection of DA release.

These data indicate that dynamic, glutamate-dependent modulation of striatal DA release requires H<sub>2</sub>O<sub>2</sub> that originates from mitochondria, rather than MAO or NADPH oxidase. This does not exclude a role for MAO-dependent DA metabolism or NADPH oxidase as sources of H<sub>2</sub>O<sub>2</sub> and/or  $\cdot O_2^-$  that might participate in other aspects of neuronal function. For example, Kulagina and Michael (86) using amperometric microensors to detect extracellular H<sub>2</sub>O<sub>2</sub> in the striatum *in vivo* found an initial increase in H<sub>2</sub>O<sub>2</sub> during electrical stimulation of the dopaminergic median forebrain bundle followed by a prolonged increase in extracellular H<sub>2</sub>O<sub>2</sub>. The initial peak is not altered in animals administered an MAO inhibitor; however the prolonged increase is largely prevented, indicating that MAO metabolism can be an important source of H<sub>2</sub>O<sub>2</sub> on a time-scale of minutes. Similarly, NADPH oxidase has been shown to be a key source of  $\cdot O_2^-$  that is required for some aspects of NMDA receptor signaling in the hippocampus (81), including regulation of long-term potentiation (82).

#### *False H<sub>2</sub>O<sub>2</sub> signaling during mitochondrial dysfunction*

Importantly, suppression of striatal DA release also occurs during unregulated generation of H<sub>2</sub>O<sub>2</sub> when mitochondrial complex I is partially inhibited by nanomolar concentrations of rotenone (19), which are sufficient to increase H<sub>2</sub>O<sub>2</sub> production in isolated mitochondria (137). After 30 min in 50 nM rotenone, evoked [DA]<sub>o</sub> falls by ~30%; release suppression can be prevented by catalase or by  $K_{ATP}$ -channel blockade, with no change in striatal ATP content *versus* control (19). Together, these data confirm H<sub>2</sub>O<sub>2</sub>-dependent  $K_{ATP}$  channel activation in the effects of rotenone on DA release. It should also be noted that rotenone-induced suppression of DA release is seen with single-pulse, as well as multiple-pulse stimulation, indicating that enhanced H<sub>2</sub>O<sub>2</sub> generation during mitochondrial inhibition does not require AMPAR activation, but rather reflects a direct effect on mitochondrial activity (19). Importantly, decreased activity of mitochondrial complex I is seen in the SNc in *postmortem* samples from individuals with Parkinson's disease (119), leading to the hypothesis that mitochondrial dysfunction is a contributing fac-

tor to DA neuron degeneration in Parkinson's (61, 66, 98). Our findings add a new perspective to the understanding of consequences of mitochondrial dysfunction, whereby 'false'  $H_2O_2$  signaling contributes to *functional* DA denervation by inhibiting DA release, as well as to anatomical degeneration of the nigrostriatal DA pathway.

### THE BRAIN ANTIOXIDANT NETWORK: PERMISSIVE, YET PROTECTIVE

As discussed above, oxidative damage by endogenous ROS is prevented by the brain antioxidant network, which includes low molecular weight antioxidants, enzymes, and repair systems (42, 44, 52, 93, 111, 142). Intriguingly, however, antioxidant regulation differs between neurons and glia, with higher levels of GSH and GSH-related enzymes in glia than in neurons (45, 50, 90, 106, 108, 113, 124, 135), but higher levels of ascorbate and the ascorbate transporter, SVCT2, in neurons than in glia (21, 113, 136). This differentiation could reflect the need for ROS signaling in neurons, with additional protection from oxidative damage provided by surrounding glia, as discussed further below. Consistent with this hypothesis, evidence from cultured cells suggest that glia play a critical role in protecting neurons from oxidative stress (45, 51, 53, 54, 130). Moreover, the ability of glia to protect neurons in culture is abolished by inhibition of GSH synthesis (53), as well as inhibition of GSH peroxidase or the major cellular peroxidase, catalase (45, 49).

We recently examined the neuroprotective role of glial antioxidants in a more nearly intact neuronal–glial microenvironment than possible in cell culture by comparing the consequences of oxidative stress caused by elevated  $H_2O_2$  in guinea pig and rat brain slices (13). This comparison was based on the rationale that the ratio of glia to neurons is higher in guinea pig brain than in rat brain, given the lower neuron density of guinea pig versus rat brain (133) and the relative constancy of glial density across species (20, 62, 69, 113, 134). We found initially that pathophysiological consequences of  $H_2O_2$  exposure seen in rat brain slices, including hyperexcitability, indicated by epileptiform activity in the hippocampus (10), and edema (26), are absent in guinea pig slices (13). The higher tolerance of guinea pig brain versus rat brain tissue to  $H_2O_2$  exposure implies that the higher glia-to-neuron ratio in this species provides additional antioxidant protection, particularly from glia.

We therefore examined the contributions of GSH synthesis, GSH peroxidase, and catalase to the resistance of guinea pig brain tissue to  $H_2O_2$  challenge and whether exogenous ascorbate could compensate for the loss of any of these components of the antioxidant network. After inhibition of any one of these antioxidant enzymes in guinea pig brain,  $H_2O_2$  exposure causes the pathological consequences typically seen in rat slices (13). For example, after GSH peroxidase inhibition by MCS or catalase inhibition by ATZ in guinea pig hippocampal slices, recovery of evoked population spike amplitude during washout of  $H_2O_2$  is delayed compared to that in control slices and is accompanied by epileptiform activity. However, when ascorbate is included at its normal extracellular

concentration of 400  $\mu M$  (111) during  $H_2O_2$  washout, these pathophysiological consequences of exogenous  $H_2O_2$  exposure are prevented in peroxidase-inhibited guinea pig hippocampal slices (13). Inclusion of ascorbate during  $H_2O_2$  washout also prevents  $H_2O_2$ -induced epileptiform activity in rat hippocampal slices (10).

In contrast to the efficacy of ascorbate in preventing pathological consequences of *exogenous*  $H_2O_2$ , this antioxidant and  $\cdot OH$  scavenger has no effect on the modulation of striatal DA release by *endogenously generated*  $H_2O_2$  (12). This important observation indicates not only that ascorbate permits  $H_2O_2$ -dependent signaling in striatum, but also that inhibition of DA release is a direct effect of  $H_2O_2$ , rather than  $\cdot OH$ . Thus, ascorbate is ideally suited as a key neuronal antioxidant because of its ability to permit  $H_2O_2$  signaling, yet prevent pathological consequences that could occur from unregulated  $H_2O_2$  generation and  $\cdot OH$  production.

### WHAT ARE PHYSIOLOGICALLY RELEVANT CONCENTRATIONS OF INTRACELLULAR $H_2O_2$ ?

Studies in isolated brain mitochondria suggest that the amount of  $H_2O_2$  produced during oxidative phosphorylation can reach 5% of the amount of  $O_2$  consumed (6). Given that the rate of  $O_2$  consumption in gray matter is 2–5  $\mu mol/g$  tissue wet weight per min (68, 91), or 2–5 mM (assuming 1 g = 1 mL), up to 250  $\mu M$   $H_2O_2$  could be generated every minute within brain neuropil. Activity-dependent  $H_2O_2$  generation would be expected to be localized to neurons rather than glia, because of the roughly 10-fold higher rate of neuronal  $O_2$  consumption (121). Absolute concentration of  $H_2O_2$  in a given cell at any time will depend not only on the activity of sources of  $H_2O_2$ , but also on the activity of the local antioxidant network, especially GSH peroxidase and catalase (42).

At the present time, there is little consensus on the normal range of intracellular  $H_2O_2$  concentration in brain cells. Accurate assessment of brain cell concentration has been hindered in part by the characteristics of first-generation  $H_2O_2$ -sensitive fluorescent dyes, including  $H_2DCF$ , which becomes fluorescent DCF after oxidation by  $H_2O_2$  in an irreversible reaction that precludes accurate calibration (14, 100). Direct dye calibration is further complicated by the typically high cellular activities of GSH peroxidase and catalase in brain tissue, which rapidly deplete initial levels of exogenously applied  $H_2O_2$  (see Ref. 52 for review). As discussed further below, confirmation of actual  $H_2O_2$  levels required for signaling awaits a new generation of fluorescent dyes or other detection methods that will allow quantitative assessment of intracellular  $H_2O_2$  concentration.

Nonetheless, there have been a number of attempts to estimate normal intracellular  $H_2O_2$  concentration using biochemical methods. For example, it has been estimated that during steady-state exposure of a non-neuronal cell line, Jurkat T-cells, to micromolar levels of exogenous  $H_2O_2$ , intracellular  $H_2O_2$  concentration is maintained at a level that is sevenfold lower than that in the medium, because of intracellular peroxidase activity (4). These data were subsequently used to make

the argument that normal intracellular H<sub>2</sub>O<sub>2</sub> concentration cannot exceed ~1  $\mu$ M, because the threshold for initiation of apoptosis in Jurkat T-cells was between 5 and 10  $\mu$ M (5, 128).

However, our own data from guinea pig brain slices suggest that *transient* intracellular H<sub>2</sub>O<sub>2</sub> elevation can far exceed 1  $\mu$ M without irreversible damage. As discussed above, inhibition of endogenous GSH peroxidase with MCS leads to enhanced DCF fluorescence in DA neurons of the SNc, with consequent K<sub>ATP</sub>-channel dependent hyperpolarization in ~50% of recorded cells (14). Application of *exogenous* H<sub>2</sub>O<sub>2</sub> causes a similar response in these H<sub>2</sub>O<sub>2</sub>-responsive neurons, when applied at a concentration of 1.5 mM. Similarly, as discussed above, DA release elicited by local pulse-train stimulation (30 pulses, 10 Hz) in the striatum is suppressed by 30–40% when GSH peroxidase is inhibited or when 1.5 mM H<sub>2</sub>O<sub>2</sub> is applied (12, 38, 39). If a sevenfold extra- to intracellular gradient in H<sub>2</sub>O<sub>2</sub> is assumed for conditions of exogenous H<sub>2</sub>O<sub>2</sub> application, it would suggest that intracellular levels reached during GSH peroxidase inhibition by MCS might transiently exceed 200  $\mu$ M. Importantly, the effects of exogenous H<sub>2</sub>O<sub>2</sub> and MCS in both midbrain and striatum are reversible and are not accompanied by loss of tissue DA content or evidence of oxidative damage (12, 38). Moreover, as already noted, MCS-induced suppression of striatal DA release does not involve formation of toxic  $\cdot$ OH (12), in contrast to induction of apoptosis in Jurkat T-cells, which is  $\cdot$ OH-dependent (5).

### TECHNICAL ISSUES IN H<sub>2</sub>O<sub>2</sub> DETECTION: EMPHASIS ON DCF IMAGING

A variety of experimental tools is available to address the biological function of H<sub>2</sub>O<sub>2</sub>, with known caveats and limitations for the use of each of these. Most of the caveats are related to the specificity of available agents, from catalase, which can metabolize other hydroperoxides in addition to H<sub>2</sub>O<sub>2</sub>, to H<sub>2</sub>DCF, which can be oxidized to fluorescent DCF by many ROS, as discussed further below. Consequently, no single agent or technique can provide conclusive evidence of H<sub>2</sub>O<sub>2</sub> involvement; however, a *combination* of methods can, as we have demonstrated in our studies of H<sub>2</sub>O<sub>2</sub> in the nigrostriatal pathway (12, 14, 19).


#### Fluorescence imaging with DCF and other indicator dyes

Fluorescence imaging using H<sub>2</sub>DCF has been used for over 30 years to detect increased production of H<sub>2</sub>O<sub>2</sub> and other ROS (14, 33, 71, 109, 114, 115). Previous examination of the chemistry of this dye indicates that H<sub>2</sub>O<sub>2</sub>, a mild oxidant, is less effective than stronger oxidants, like  $\cdot$ OH, in oxidizing H<sub>2</sub>DCF to form fluorescent DCF. For example, LeBel *et al.* (87) reported that the increase in DCF fluorescence in the presence of exogenous H<sub>2</sub>O<sub>2</sub> is attenuated by ~90% when H<sub>2</sub>O<sub>2</sub> was applied along with a metal ion chelator, deferoxamine, indicating that the primary oxidant is  $\cdot$ OH. LeBel *et al.* also found that DCF fluorescence intensity is amplified when H<sub>2</sub>O<sub>2</sub> was applied with added iron (Fe<sup>2+</sup>) (87). However, two aspects of these studies are often overlooked. First, at least


10% of the H<sub>2</sub>O<sub>2</sub>-dependent increase in DCF fluorescence persists in the presence of deferoxamine, suggesting that H<sub>2</sub>O<sub>2</sub> can indeed form fluorescent DCF directly. Second, when H<sub>2</sub>O<sub>2</sub> concentration is increased in the presence of Fe<sup>2+</sup>, DCF fluorescence increases with a strict linear dependence on H<sub>2</sub>O<sub>2</sub> concentration (Fig. 4; from 87), demonstrating a clear H<sub>2</sub>O<sub>2</sub>-dependent response. These findings indicate that DCF fluorescence can be 'H<sub>2</sub>O<sub>2</sub>-sensitive,' even when activation is indirect (*i.e.*, via  $\cdot$ OH).

Our own studies of H<sub>2</sub>O<sub>2</sub>-dependent regulation of DA neuron activity support this view (14). We examined the concentration–response of DCF fluorescence intensity in SNc DA neurons with increasing concentrations of the GSH peroxidase inhibitor MCS (Fig. 3). Because it is not possible to calibrate fluorescence intensity of DCF (or other currently available ROS-sensitive dyes), DCF cannot be used to quantify ROS. However, fluorescence intensity can be used as an index of relative changes in the extent and rate of ROS generation when a single variable is changed, as in our studies of progressive GSH peroxidase inhibition in tonically active DA neurons. Under these conditions, DCF fluorescence increases linearly with increasing MCS concentration [*i.e.*, increasing GSH peroxidase inhibition (Fig. 3)], consistent with an H<sub>2</sub>O<sub>2</sub>-dependent signal (14).

Of course, peroxidase inhibition should produce a relatively 'clean' increase in H<sub>2</sub>O<sub>2</sub>, whereas most other conditions would not. Such studies mandate corroboration of DCF imaging data with other evidence to confirm H<sub>2</sub>O<sub>2</sub> involvement. For example, in our studies of false H<sub>2</sub>O<sub>2</sub> signaling in the striatum under conditions of rotenone-induced mitochondrial dysfunction, we used DCF imaging to reveal the time course of ROS generation in medium spiny neurons (19). Two additional sets of data helped confirm that the observed rotenone-induced increase in DCF fluorescence is largely H<sub>2</sub>O<sub>2</sub> dependent. First, the increase in fluorescence is markedly attenuated in the presence of exogenous catalase (Fig. 5). Catalase also prevents rotenone-induced effects on DA release and medium spiny neuron membrane properties, further



**FIG. 4. Concentration–response curve of H<sub>2</sub>DCF oxidation in the presence of H<sub>2</sub>O<sub>2</sub>.** “The Fe<sup>2+</sup> concentration was held constant at 10  $\mu$ M, and all incubations were performed at 37°C for 5 min. The data were obtained from three independent experiments and are expressed as the means  $\pm$  SEM.” (Figure and legend from Ref. 87.)




**FIG. 5. Rotenone-induced increase in DCF fluorescence intensity (FI) is  $H_2O_2$  dependent.** Representative time course of DCF FI changes; a modified grayscale was used to enhance the contrast between basal and rotenone-induced DCF images. (A) Under control conditions (heat-inactivated catalase, I-cat), rotenone (50 nM) causes a ~50% increase in DCF FI in a medium spiny neuron in a striatal slice. (B) Rotenone-enhanced FI is prevented by active catalase (500 U/mL;  $n = 3$ ), confirming the primary dependence of the DCF signal on  $H_2O_2$  (data from Ref. 19).

supporting a role for *functionally relevant*  $H_2O_2$  generation (19). Second, to address possible contributions from metal ion-dependent  $\cdot OH$ , we examined whether the rotenone-induced increases in DCF fluorescence persists in the presence of deferoxamine. With 1 mM deferoxamine in both the patch-pipette backfill solution and in the superfusing ACSF, the DCF signal was attenuated by ~30% versus control ( $p < 0.001$ ,  $n = 3$ ) (Fig. 6), suggesting a ~30% contribution of  $\cdot OH$  to the DCF signal. Together, these data indicate that, the DCF signal under these conditions is predominantly  $H_2O_2$  dependent and confirm the value of DCF imaging as a companion technique in studies of  $H_2O_2$ -dependent neuromodulation.

#### Other methods for *in situ* $H_2O_2$ detection

One other currently available dye for  $H_2O_2$  imaging is Amplex Red (145), which has been used successfully in studies of  $H_2O_2$  generation in isolated mitochondria (e.g., 137). Like the oxidation of  $H_2DCF$  to DCF, however, the oxidation of Amplex Red to its fluorescent product is irreversible, also precluding dye calibration. Irreversible activation also means that neither DCF nor Amplex Red imaging can be used to assess the time course of  $H_2O_2$  clearance after elevation. A further drawback of Amplex Red is that its activation apparently requires exogenous peroxidase activity (145). Although there



**FIG. 6. Effect of metal ion chelation by deferoxamine on rotenone-induced DCF fluorescence intensity (FI).** Under control conditions, rotenone (50 nM) causes the usual increase in DCF FI. However, when deferoxamine, a metal ion chelator, is included in the backfill solution of the patch-pipette used for simultaneous whole-cell recording, DCF FI is significantly lower than under control conditions ( $n = 4$ ;  $p < 0.001$ , ANOVA), indicating some contribution of  $\cdot OH$  to the DCF signal seen during partial mitochondrial inhibition by rotenone.

is endogenous GSH peroxidase and catalase in neurons, we have not had success in  $H_2O_2$  detection with Amplex Red loaded into single neurons.

Given the limitations of these currently available dyes, there is increasing interest in the development of new imaging methods to study  $H_2O_2$ . Among the most promising are boronate-based dyes, including Peroxyfluor-1 (PF1), that are cell permeable and have excellent selectivity for  $H_2O_2$  (36, 94). The specificity of PF1 and related dyes for  $H_2O_2$  comes from chemoselective boronate deprotection, rather than non-specific oxidation. Limitations include relatively slow activation and that these first generation dyes cannot readily be trapped in cells. Nonetheless, their introduction heralds an exciting new direction in dye development.

Other methods that have been used with increasing success in cultured cells, including organotypic cultures, are based on expression of redox-sensitive variants of green fluorescent proteins (ro-GFPs) (24, 28, 48, 99). In these proteins, surface-exposed cysteine pairs are introduced that allow disulfide bond formation, making the interaction with  $H_2O_2$  or other ROS a reversible process, which is an advantage over other currently available imaging agents. These probes can be targeted to specific cells after transfection in culture or *in vivo*. At present, however, the response time of these probes is very slow, on the order of minutes. Moreover, because disulfide bond formation required to activate ro-GFPs can occur in the presence of many oxidants, evidence for an  $H_2O_2$ -dependent signal must be confirmed using other methods, as described earlier for identification of the source of DCF signals.

Lastly, electrochemical biosensors can be used to detect  $H_2O_2$  in biological systems, including in the extracellular fluid of brain tissue *in vivo* (86). Amperometric  $H_2O_2$  sensors provide the basis for detection of nonelectroactive substances, including glutamate (92) and choline (64), when coupled to selective enzymes that produce detectable  $H_2O_2$ . The



extracellular concentration of H<sub>2</sub>O<sub>2</sub> detected in striatum during electrical stimulation of the median forebrain bundle is 1–3  $\mu$ M (86). Given the relative small striatal volume taken up by DA axons, this means that the H<sub>2</sub>O<sub>2</sub> concentration attained within these activated axons would necessarily be several-fold higher. The authors suggest that detected H<sub>2</sub>O<sub>2</sub> may be derived from the oxidation of released DA in the extracellular space (86). However, this would be surprising, given that the usual homeostatically regulated concentration of ascorbate in the extracellular fluid is ~400  $\mu$ M (see Ref. 111 for review), which should be sufficient to protect the low micromolar levels of [DA]<sub>o</sub> achieved under these conditions. Our *in vitro* brain slice data also argue against DA oxidation as a primary source of activity-dependent H<sub>2</sub>O<sub>2</sub>. Blockade of AMPARs can cause a doubling of evoked [DA]<sub>o</sub> (12), yet under these same conditions, the usual stimulation-induced increase in DCF fluorescence monitored in medium spiny neurons is virtually abolished (102). These findings suggest that there is little contribution from DA oxidation to H<sub>2</sub>O<sub>2</sub> generation, even in brain slice preparations, in which there is little residual extracellular ascorbate (111).

## SUMMARY AND IMPLICATIONS

In our first report of DA release modulation by endogenous H<sub>2</sub>O<sub>2</sub> in striatum (38), we suggested that H<sub>2</sub>O<sub>2</sub> might be generated presynaptically at DA synapses to serve as an autoinhibitory signal that would limit DA release after axonal activation, given the close apposition of mitochondria to presynaptic sites in DA axons (*e.g.*, 96). However, our subsequent studies showed that generation of modulatory H<sub>2</sub>O<sub>2</sub> requires AMPAR activation and can be fine-tuned by GABA<sub>A</sub>R activation. These findings argue against primary H<sub>2</sub>O<sub>2</sub> generation in DA axons, since they lack AMPARs and GABA<sub>A</sub>Rs (22, 40, 63). Rather, we found that generation of modulatory H<sub>2</sub>O<sub>2</sub> must occur in non-DA cells or processes then diffuse to DA axons to inhibit DA release. Our data suggest that regulation of striatal DA release by glutamate and GABA involves a triad of DA, glutamate, and GABA synapses, separated by a few micrometers on the dendrites of medium spiny neurons (22, 40, 63, 125), and bound together *functionally* by diffusible H<sub>2</sub>O<sub>2</sub>. Regardless of the source, endogenously generated H<sub>2</sub>O<sub>2</sub> reverses conventional glutamatergic excitation by opening SUR1-based K<sub>ATP</sub> channels to inhibit striatal DA release. This discovery represents a new and potentially important mechanism of external regulation of DA release that establishes a formerly ‘missing link’ in the reciprocal relationship between DA and glutamate in striatum. Moreover, because DA-glutamate dysfunction has been implicated as a causal factor in Parkinson disease (37, 65, 97), schizophrenia (46, 118), and addiction (73, 83), exploration of this process may also suggest novel pathways through which dysfunction could occur.

Thus, neuromodulation by H<sub>2</sub>O<sub>2</sub> can be a double-edged sword: although activity-dependent H<sub>2</sub>O<sub>2</sub> generation may provide important regulation of DA release, an imbalance between H<sub>2</sub>O<sub>2</sub> generation and metabolism could result in oxidative stress, which has been implicated in nigrostriatal degeneration in Parkinson’s disease (42, 43, 97, 126, 139) and,

more recently, as a causal factor in schizophrenia (47, 141). Thus, loss of normal H<sub>2</sub>O<sub>2</sub> regulation might contribute to DA-system pathology. It is relevant to note, therefore, that inhibition of GSH peroxidase by MCS leads to DA-neuron hyperpolarization (14) and suppression of somatodendritic DA release in the SNc (39); however, MCS does not inhibit DA release in the adjacent ventral tegmental area (VTA) (39). This difference between SNc and VTA is potentially important, because DA neurons of the SNc degenerate in Parkinson’s whereas those in the VTA are relatively spared (60, 140).

Lastly, it should be noted that neuromodulation by H<sub>2</sub>O<sub>2</sub> is not limited to the nigrostriatal system. Other studies have shown that H<sub>2</sub>O<sub>2</sub> influences characteristics of long-term potentiation in the hippocampus (9, 77, 78), which has implications for memory formation. Diffusible H<sub>2</sub>O<sub>2</sub> also plays a role in neuron–glia signaling in the hippocampus, in which neuronal activation leads to H<sub>2</sub>O<sub>2</sub>-dependent phosphorylation of myelin basic protein in oligodendrocytes (8). These data, as well as our own findings (12, 14), demonstrate that H<sub>2</sub>O<sub>2</sub> can act as an intracellular signaling agent *and* as a diffusible messenger. For H<sub>2</sub>O<sub>2</sub> to act at both intracellular and potentially distant targets requires that the brain antioxidant network is structured to allow functional levels of H<sub>2</sub>O<sub>2</sub> and other ROS, while at the same time preventing oxidative stress. These requirements add a previously unrecognized dimension to oxidant management. We have proposed (13) that key features of such a permissive environment are the predominance of cytosolic GSH peroxidase activity in glia, with subcompartmentalization of catalase in peroxisomes in both glia and neurons, and the predominance of •OH-scavenging ascorbate in neurons (42, 52, 111, 113).

## ACKNOWLEDGMENTS

The authors gratefully acknowledge support from NIH/NINDS grants NS-36362 and NS-45325 and from the National Parkinson Foundation.

## ABBREVIATIONS

ACSF, artificial cerebrospinal fluid; AMPAR, AMPA receptor; ATZ, 3-aminotriazole; CNS, central nervous system; DA, dopamine; [DA]<sub>o</sub>, extracellular dopamine concentration; DCF, dichlorofluorescein; GABA<sub>A</sub>R, GABA<sub>A</sub> receptor; GSH, glutathione; H<sub>2</sub>DCF, 2,7 dichlorodihydrofluorescein; K<sub>ATP</sub> channels, ATP-sensitive K<sup>+</sup> channels; MCS, mercaptosuccinate; PF1, Peroxyfluor-1; roGFP, redox-sensitive green fluorescent protein; ROS, reactive oxygen species; SNc, substantia nigra pars compacta; SUR, sulfonylurea receptor site; VTA, ventral tegmental area.

## REFERENCES

1. Adam–Vizi V. Production of reactive oxygen species in brain mitochondria: contribution by electron transport chain and non-

- electron transport chain sources. *Antioxid Redox Signal* 7: 1140–1149, 2005.
2. Aguilar-Bryan L, Clement JPT, Gonzalez G, Kunjilwar K, Babenko A, and Bryan J. Toward understanding the assembly and structure of  $K_{ATP}$  channels. *Physiol Rev* 78: 227–245, 1998.
3. Albin RL, Young AB, and Penney JB. The functional anatomy of basal ganglia disorders. *Trends Neurosci* 12: 366–375, 1989.
4. Antunes F and Cadenas E. Estimation of  $H_2O_2$  gradients across biomembranes. *FEBS Lett* 475: 121–126, 2000.
5. Antunes F and Cadenas E. Cellular titration of apoptosis with steady state concentrations of  $H_2O_2$ : submicromolar levels of  $H_2O_2$  induce apoptosis through Fenton chemistry independent of the cellular thiol state. *Free Radic Biol Med* 30:1008–1018, 2001.
6. Arnaiz SL, Coronel MF, and Boveris A. Nitric oxide, superoxide, and hydrogen peroxide production in brain mitochondria after haloperidol treatment. *Nitric Oxide* 3: 235–243, 1999.
7. Ashcroft FM and Gribble FM. Correlating structure and function in ATP-sensitive  $K^+$  channels. *Trends Neurosci* 21: 288–294, 1998.
8. Atkins CM and Sweatt JD. Reactive oxygen species mediate activity-dependent neuron-glia signaling in output fibers of the hippocampus. *J Neurosci* 19: 7241–7248, 1999.
9. Auerbach JM and Segal M. Peroxide modulation of slow onset potentiation in rat hippocampus. *J Neurosci* 17: 8695–8701, 1997.
10. Avshalumov MV and Rice ME. NMDA-receptor activation mediates hydrogen peroxide-induced pathophysiology in rat hippocampal slices. *J Neurophysiol* 87: 2896–2903, 2002.
11. Avshalumov MV and Rice ME. Activation of ATP-sensitive  $K^+$  ( $K_{ATP}$ ) channels by  $H_2O_2$  underlies glutamate-dependent inhibition of striatal dopamine release. *Proc Natl Acad Sci USA* 100: 11729–11734, 2003.
12. Avshalumov MV, Chen BT, Marshall SP, Peña DM, and Rice ME. Glutamate-dependent inhibition of dopamine release in striatum is mediated by a new diffusible messenger,  $H_2O_2$ . *J Neurosci* 23: 2744–2750, 2003.
13. Avshalumov MV, MacGregor DG, Seghal LM, and Rice ME. The glial antioxidant network and neuronal ascorbate: permissive yet protective for  $H_2O_2$  signaling. *Neuron Glia Biol* 1: 365–376, 2004.
14. Avshalumov MV, Chen BT, Koós T, Tepper JM, and Rice ME. Endogenous hydrogen peroxide regulates the excitability of midbrain dopamine neurons via ATP-sensitive potassium channels. *J Neurosci* 25: 4222–4231, 2005.
15. Babenko AP, Gonzalez G, and Bryan J. Pharmacology of sulfonylurea receptors. Separate domains of the regulatory subunits of  $K_{ATP}$  channel isoforms are required for selective interaction with  $K^+$  channel openers. *J Biol Chem* 275: 717–720, 2000.
16. Babior BM. The respiratory burst of phagocytes. *J Clin Invest* 73: 599–601, 1984.
17. Babior BM. NADPH oxidase: an update. *Blood* 93: 1464–1476, 1999.
18. Bao L and Rice ME. Mitochondrial  $H_2O_2$  mediates glutamate-dependent inhibition of striatal dopamine release, 2004 *Abstract Viewer/Itinerary Planner*, Washington, DC: Society for Neuroscience, 46.7, 2004.
19. Bao L, Avshalumov MV, and Rice ME. Mitochondrial inhibition causes functional dopamine denervation and striatal medium spiny neurons depolarization via increased  $H_2O_2$ , not decreased ATP. *J Neurosci* 25: 10029–10040, 2005.
20. Bass NH, Hess HH, Pope A, and Thalheimer C. Quantitative cytoarchitectonic distribution of neurons, glia and DNA in rat cerebral cortex. *J Comp Neurol* 143: 481–490, 1971.
21. Berger UV and Hediger MA. The vitamin C transporter SVCT2 is expressed by astrocytes in culture but not *in situ*. *Neuroreport* 11: 1395–1399, 2000.
22. Bernard V and Bolam JP. Subcellular and subsynaptic distribution of the NR1 subunit of the NMDA receptor in the neostriatum and globus pallidus of the rat: colocalization at synapses with the GluR2/3 subunit of the AMPA receptor. *Eur J Neurosci* 10: 3721–3738, 1998.
23. Bindokas VP, Jordan J, Lee CC, and Miller RJ. Superoxide production in rat hippocampal neurons: selective imaging with hydroethidine. *J Neurosci* 16: 1324–1336, 1996.
24. Björnberg O, Ostergaard H, and Winther JR. Measuring intracellular redox conditions using GFP-based sensors. *Antioxid Redox Signal* 8: 354–361, 2006.
25. Boveris A and Chance B. The mitochondrial generation of hydrogen peroxide: general properties and the effect of hyperbaric oxygen. *Biochem J* 134: 707–716, 1973.
26. Brahma B, Forman RE, Stewart EE, Nicholson C, and Rice ME. Ascorbate inhibits brain slice edema. *J Neurochem* 74: 1263–1270, 2000.
27. Cannon CM and Bseikri MR. Is dopamine required for natural reward? *Physiol Behav* 81: 741–748, 2004.
28. Cannon MB and Remington SJ. Re-engineered redox-sensitive green fluorescent protein for improved response rate. *Protein Sci* 15: 45–57, 2006.
29. Cao W, Carney JM, Duchon A, Floyd RA, and Chevion M. Oxygen free radical involvement in ischemia and reperfusion injury to brain. *Neurosci Lett* 88: 233–238, 1988.
30. Carlsson A. Treatment of Parkinson's with L-DOPA. The early discovery phase, and a comment on current problems. *J Neural Transm* 109: 777–787, 2002.
31. Carriedo SG, Sensi SL, Yin HZ, and Weiss JH. AMPA exposures induce mitochondrial  $Ca^{2+}$  overload and ROS generation in spinal motor neurons *in vitro*. *J Neurosci* 20: 240–250, 2000.
32. Castner SA, Goldman-Rakic PS, and Williams GV. Animal models of working memory: insights for targeting cognitive dysfunction in schizophrenia. *Psychopharmacol (Berl)* 174: 111–125, 2004.
33. Cathcart R, Schwieters E, and Ames BN. Detection of picomole levels of hydroperoxides using a fluorescent dichlorofluorescein assay. *Anal Biochem* 134: 111–116, 1983.
34. Chan PH. Mitochondria and neuronal death/survival signaling pathways in cerebral ischemia. *Neurochem Res* 29: 1943–1949, 2004.
35. Chance B, Sies H, and Boveris A. Hydroperoxide metabolism in mammalian organs. *Physiol Rev* 59: 527–605, 1979.
36. Chang MCY, Pralle A, Isacoff EY, and Chang CJ. A selective, cell-permeable optical probe for hydrogen peroxide in living cells. *Am Chem Soc* 126: 15392–15393, 2004.
37. Chase TN and Oh JD. Striatal dopamine- and glutamate-mediated dysregulation in experimental parkinsonism. *Trends Neurosci* 23: S86–S91, 2000.
38. Chen BT, Avshalumov MV, and Rice ME.  $H_2O_2$  is a novel, endogenous modulator of synaptic dopamine release. *J Neurophysiol* 85: 2468–2476, 2001.
39. Chen BT, Avshalumov MV, and Rice ME. Modulation of somatodendritic dopamine release by endogenous  $H_2O_2$ : susceptibility in substantia nigra but resistance in the ventral tegmental area. *J Neurophysiol* 87: 1155–1158, 2002.
40. Chen Q, Veenman L, Knopp K, Yan Z, Medina L, Song WJ, Surmeier DJ, and Reiner A. Evidence for the preferential localization of glutamate receptor-1 subunits of AMPA receptors to the dendritic spines of medium spiny neurons in rat striatum. *Neuroscience* 83: 749–761, 1998.
41. Coetzee WA, Nakamura TY, and Faivre JF. Effects of thiol-modifying agents on  $K_{ATP}$  channels in guinea pig ventricular cells. *Am J Physiol* 269: H1625–H1633, 1995.
42. Cohen G. Enzymatic/nonenzymatic sources of oxyradicals and regulation of antioxidant defenses. *Ann NY Acad Sci* 738: 8–14, 1994.
43. Cohen G, Farooqui R, and Kesler N. Parkinson disease: a new link between monoamine oxidase and mitochondrial electron flow. *Proc Natl Acad Sci USA* 94: 4890–4894, 1997.
44. Davies KJA. Proteolytic systems as secondary antioxidant defenses. In: Chow, C.K. (Ed.), *Cellular Antioxidant Defense Mechanisms*. CRC Press, Boca Raton, pp. 25–67, 1988.
45. Desagher S, Glowinski J, and Premont J. Astrocytes protect neurons from hydrogen peroxide toxicity. *J Neurosci* 16: 2553–2562, 1996.
46. Deutsch SL, Rosse RB, Schwartz BL, and Mastropaulo J. A revised excitotoxic hypothesis of schizophrenia: therapeutic implications. *Clin Neuropharmacol* 24: 43–49, 2001.
47. Do KQ, Trabesinger AH, Kirsten-Kruger M, Lauer CJ, Dydak U, Hell D, Holsboer F, Boesiger P, and Cuenod M. Schizophrenia: glutathione deficit in cerebrospinal fluid and prefrontal cortex *in vivo*. *Eur J Neurosci* 12: 3721–3728, 2000.
48. Dooley CT, Dore TM, Hanson GT, Jackson WC, Remington SJ, and Tsein RY. Imaging dynamic redox changes in mammalian

- cells with green fluorescent indicators. *J Biol Chem* 279: 22284–22293, 2004.
49. Dringen R and Hamprecht B. Involvement of glutathione peroxidase and catalase in the disposal of exogenous hydrogen peroxide by cultured astroglial cells. *Brain Res* 759: 67–75, 1997.
  50. Dringen R and Hirrlinger J. Glutathione pathways in the brain. *Biol Chem* 384: 505–516, 2003.
  51. Dringen R, Kussmaul L, Gutterer JM, Hirrlinger J, and Hamprecht B. The glutathione system of peroxide detoxification is less efficient in neurons than in astroglial cells. *J Neurochem* 72: 2523–2530, 1999.
  52. Dringen R, Pawlowski PG, and Hirrlinger J. Peroxide detoxification by brain cells. *J Neurosci Res* 79: 157–165, 2005.
  53. Drukarch B, Schepens E, Jongenelen CA, Stoof JC, and Langeveld CH. Astrocyte-mediated enhancement of neuronal survival is abolished by glutathione deficiency. *Brain Res* 770: 123–130, 1997.
  54. Drukarch B, Schepens E, Stoof JC, Langeveld CH, and Van Muiswinkel FL. Astrocyte-enhanced neuronal survival is mediated by scavenging of extracellular reactive oxygen species. *Free Rad Biol Med* 25: 217–220, 1998.
  55. Dugan LL, Sensi SL, Canzoniero LM, Handran SD, Rothman SM, Lin TS, Goldberg MP, and Choi DW. Mitochondrial production of reactive oxygen species in cortical neurons following exposure to N-methyl-D-aspartate. *J Neurosci* 15: 6377–6388, 1995.
  56. Dunn-Meynell AA, Routh VH, McArdle JJ, and Levin BE. Low-affinity sulfonylurea binding sites reside on neuronal cell bodies in the brain. *Brain Res* 745: 1–9, 1997.
  57. Ebadi M, Srinivasan SK, and Baxi MD. Oxidative stress and antioxidant therapy in Parkinson's disease. *Prog Neurobiol* 48: 1–19, 1996.
  58. Esposito F, Ammendola R, Faraonio R, Russo T, and Cimino F. Redox control of signal transduction, gene expression and cellular senescence. *Neurochem Res* 29: 617–628, 2004.
  59. Evans AH and Lees AJ. Dopamine dysregulation syndrome in Parkinson's disease. *Curr Opin Neurol* 17: 393–398, 2004.
  60. Fearnley J and Lees AJ. Aging and Parkinson's disease: substantia nigra regional selectivity. *Brain* 114: 2283–2301, 1991.
  61. Fiskum G, Starkov A, Polster BM, and Chinopoulos C. Mitochondrial mechanisms of neural cell death and neuroprotective interventions in Parkinson's disease. *Ann NY Acad Sci* 991: 111–119, 2003.
  62. Friede R. Der quantitative Anteil der Glia an der Cortexentwicklung. *Acta Anatomica* 20: 290–296, 1954.
  63. Fujiyama F, Fritschy JM, Stephenson FA, and Bolam JP. Synaptic localization of GABA<sub>A</sub> receptor subunits in the striatum of the rat. *J Comp Neurol* 416: 158–172, 2000.
  64. Garguilo MG and Michael AC. Amperometric microsenors for monitoring choline in the extracellular fluid of brain. *J Neurosci Meth* 70: 73–82, 1996.
  65. Greenamyre JT. Glutamatergic influences on the basal ganglia. *Clin Neuropharmacol* 24: 65–70, 2001.
  66. Greenamyre JT, Sherer TB, Betarbet R, and Panov AV. Complex I and Parkinson's disease. *IUBMB Life* 52: 135–141, 2001.
  67. Haddad JJ. Antioxidant and prooxidant mechanisms in the regulation of redox(y)-sensitive transcription factors. *Cell Signal* 14: 879–897, 2002.
  68. Hagerdal M, Harp J, Nilsson L, and Siesjö BK. The effect of induced hypothermia upon oxygen consumption in the rat brain. *J Neurochem* 24: 311–316, 1975.
  69. Haug H. Brain sizes, surfaces, and neuronal sizes of the cortex cerebri: a stereological investigation of man and his variability and a comparison with some mammals (primates, whales, marsupials, insectivores, and one elephant). *Am J Anat (now Developmental Dynamics)* 180: 126–142, 1987.
  70. Häusser MA, de Weille JR, and Lazdunski M. Activation by cromakalim of pre- and post-synaptic ATP-sensitive K<sup>+</sup> channels in substantia nigra. *Biochem Biophys Res Comm* 174: 909–914, 1991.
  71. Homan-Muller JW, Weening RS, and Roos D. Production of hydrogen peroxide by phagocytizing human granulocytes. *J Lab Clin Med* 85: 198–207, 1975.
  72. Hung HC and Lee EH. MPTP produces differential oxidative stress and antioxidative responses in the nigrostriatal and mesolimbic dopaminergic pathways. *Free Radic Biol Med* 24: 76–84, 1998.
  73. Hyman SE and Malenka RC. Addiction and the brain: the neurobiology of compulsion and its persistence. *Nat Rev Neurosci* 2: 695–703, 2001.
  74. Hyslop PA, Zhang Z, Pearson DV, and Phebus LA. Measurement of striatal H<sub>2</sub>O<sub>2</sub> by microdialysis following global forebrain ischemia and reperfusion in the rat: correlation with the cytotoxic potential of H<sub>2</sub>O<sub>2</sub> *in vitro*. *Brain Res* 671: 181–186, 1995.
  75. Ichinari K, Kakei M, Matsuoka T, Nakashima H, and Tanaka H. Direct activation of the ATP-sensitive potassium channel by oxygen free radicals in guinea pig ventricular cells: its potentiation by MgADP. *J Mol Cell Cardiol* 28: 1867–1877, 1996.
  76. Inagaki N, Gonoi T, Clement JP, Wang CZ, Aguilar-Bryan L, Bryan J, and Seino S. A family of sulfonylurea receptors determines the pharmacological properties of ATP-sensitive K<sup>+</sup> channels. *Neuron* 16: 1011–1017.
  77. Kamsler A and Segal M. Hydrogen peroxide modulation of synaptic plasticity. *J Neurosci* 23: 269–276, 2003.
  78. Kamsler A and Segal M. Hydrogen peroxide as a diffusible signal molecule in synaptic plasticity. *Mol Neurobiol* 29: 167–178, 2004.
  79. Karschin C, Ecker C, Ashcroft FM, and Karschin A. Overlapping distribution of K<sub>ATP</sub> channel-forming Kir6.2 subunit and the sulfonylurea receptor SUR1 in rodent brain. *FEBS Lett* 401: 59–64, 1997.
  80. Kemp JM and Powell TP. The structure of the caudate nucleus of the cat: light and electron microscopy. *Philos Trans R Soc Lond B Biol Sci* 262: 383–401, 1971.
  81. Kishida KT, Pao M, Holland SM, and Klann E. NADPH oxidase is required for NMDA receptor-dependent activation of ERK in hippocampal area CA1. *J Neurochem* 94: 299–306, 2005.
  82. Knapp LT and Klann E. Role of reactive oxygen species in hippocampal long-term potentiation: contributory or inhibitory? *J Neurosci Res* 70: 1–7, 2002.
  83. Koob GF. Neurobiology of addiction. Toward the development of new therapies. *Ann NY Acad Sci* 909: 170–185, 2000.
  84. Krippeit-Drews P, Kramer C, Welker S, Lang F, Ammon HP, and Drews G. Interference of H<sub>2</sub>O<sub>2</sub> with stimulus-secretion coupling in mouse pancreatic beta-cells. *J Physiol (Lond)* 514: 471–481, 1999.
  85. Kudin AP, Debska-Vielhaber G, and Kunz WS. Characterization of superoxide production sites in isolated rat brain and skeletal muscle mitochondria. *Biomed Pharmacother* 59: 163–168, 2005.
  86. Kulagina NV and Michael AC. Monitoring hydrogen peroxide in the extracellular space of the brain with amperometric microsenors. *Anal Chem* 75: 4875–4881, 2003.
  87. LeBel CP, Ischiropoulos H, and Bondy SC. Evaluation of the probe 2',7'-dichloro-fluorescein as an indicator of reactive oxygen species formation and oxidative stress. *Chem Res Toxicol* 5: 227–231, 1992.
  88. Liss B, Bruns R, and Roeper J. Alternative sulfonylurea receptor expression defines sensitivity to K-ATP channels in dopaminergic midbrain neurons. *EMBO J* 18: 833–846, 1999.
  89. Liu Y, Fiskum G, and Schubert D. Generation of reactive oxygen species by the mitochondrial electron transport chain. *J Neurochem* 80: 780–787, 2002.
  90. Makar TK, Nedergaard M, Preuss A, Gebard AS, Perumal AS, and Cooper AJL. Vitamin E, ascorbate, glutathione, glutathione disulfide, and enzymes of oxidative metabolism in cultures of chick astrocytes and neurons: evidence that astrocytes play an important role in oxidative processes in the brain. *J Neurochem* 62: 45–53, 1994.
  91. McIlwain H and Bachelard HS. *Biochemistry and the Central Nervous System*. New York: Churchill Livingstone, pp. 59–60, 1985.
  92. McMahon CP, Rocchitta G, Serra PA, Kirwan SM, Lowry JP, and O'Neill RD. Control of the oxygen dependence of an implantable polymer/enzyme composite biosensor for glutamate. *Anal Chem* 78: 2352–2359, 2006.
  93. Meister A. Glutathione-ascorbic acid antioxidant system in animals. *J Biol Chem* 269: 9397–9400, 1994.
  94. Miller EW, Albers AE, Pralle A, Isacoff EY, and Chang CJ. Boronate-based fluorescent probes for imaging cellular hydrogen peroxide. *J Am Chem Soc* 127: 16652–16659, 2005.



95. Mourre C, Smith ML, Siesjö BK, and Lazdunski M. Brain ischemia alters the density of binding sites for glibenclamide, a specific blocker of ATP-sensitive K<sup>+</sup> channels. *Brain Res* 526: 147–152, 1990.
96. Nirenberg MJ, Chan J, Liu Y, Edwards RH, and Pickel VM. Vesicular monoamine transporter-2: immunogold localization in striatal axons and terminals. *Synapse* 26: 194–198, 1997.
97. Olanow CW and Tatton WG. Etiology and pathogenesis of Parkinson's disease. *Ann Rev Neurosci* 22: 123–144, 1999.
98. Orth M and Schapira AH. Mitochondrial involvement in Parkinson's disease. *Neurochem Int* 40: 533–541, 2002.
99. Østergaard H, Henriksen A, Hansen FG, and Winther JR. Shedding light on disulfide bond formation: engineering a redox switch in green fluorescent protein. *EMBO J* 20: 5853–5862, 2001.
100. Oyama Y, Hayashi A, Ueha T, and Maekawa K. Characterization of 2',7'-dichlorofluorescein fluorescence in dissociated mammalian brain neurons: estimation on intracellular content of hydrogen peroxide. *Brain Res* 635: 113–117, 1994.
101. Patel J and Rice ME. Monitoring dopamine release in brain slices. In: *Encyclopedia of Sensors*, Vol. 6, Grimes, C. A., Dickey, E. C., and Pishko, M. V. eds. Stevenson Ranch, California: American Scientific Publishers, pp. 313–334, 2006.
102. Patel J, Avshalumov MV, and Rice ME. Glutamate-dependent inhibition of striatal dopamine release is mediated by H<sub>2</sub>O<sub>2</sub> generated in medium spiny neurons but not in dopamine terminals, 2004 Abstract Viewer/Itinerary Planner, Washington, DC: Society for Neuroscience, 46.6, 2004.
103. Pellmar T. Electrophysiological correlates of peroxide damage in guinea pig hippocampus *in vitro*. *Brain Res* 364: 377–381, 1986.
104. Pellmar TC. Peroxide alters neuronal excitability in the CA1 region of guinea-pig hippocampus *in vitro*. *Neuroscience* 23: 447–456, 1987.
105. Pellmar TC. Use of brain slices in the study of free-radical actions. *J Neurosci Meth* 59: 93–98, 1995.
106. Peuchen S, Bolanos JP, Heales SJ, Almeida A, Duchon MR, and Clark JB. Interrelationships between astrocyte function, oxidative stress and antioxidant status within the central nervous system. *Prog Neurobiol* 52: 261–281, 1997.
107. Ramasarma T. Generation of H<sub>2</sub>O<sub>2</sub> in biomembranes. *Biochim Biophys Acta* 694: 69–93, 1982.
108. Raps SP, Lai JCK, Hertz L, and Cooper AJL. Glutathione is present in high concentrations in cultured astrocytes but not in cultured neurons. *Brain Res* 493: 398–401, 1989.
109. Reynolds IJ and Hastings TG. Glutamate induces the production of reactive oxygen species in cultured forebrain neurons following NMDA receptor activation. *J Neurosci* 15: 3318–3327, 1995.
110. Rhee SG, Kang SW, Jeong W, Chang TS, Yang KS, and Woo HA. Intracellular messenger function of hydrogen peroxide and its regulation by peroxiredoxins. *Curr Opin Cell Biol* 17: 183–189, 2005.
111. Rice ME. Ascorbate regulation and its neuroprotective role in the brain. *Trends Neurosci* 23: 209–216, 2000.
112. Rice ME and Nicholson C. Diffusion characteristics and extracellular volume fraction during normoxia and hypoxia in slices of rat neostriatum. *J Neurophysiol* 65: 264–272, 1991.
113. Rice ME and Russo-Menna I. Differential compartmentalization of brain ascorbate and glutathione between neurons and glia. *Neuroscience* 82: 1213–1223, 1998.
114. Saez JC, Kessler JA, Bennett MV, and Spray DC. Superoxide dismutase protects cultured neurons against death by starvation. *Proc Natl Acad Sci USA* 84: 3056–3059, 1987.
115. Sah R and Schwartz-Bloom RD. Optical imaging reveals elevated intracellular chloride in hippocampal pyramidal cells after oxidative stress. *J Neurosci* 19: 9209–9217, 1999.
116. Sandri G, Panfili E, and Ernster L. Hydrogen peroxide production by monoamine oxidase in isolated rat-brain mitochondria: its effect on glutathione levels and Ca<sup>2+</sup> efflux. *Biochim Biophys Acta* 1035: 300–305, 1990.
117. Sauer H, Wartenberg M, and Hescheler J. Reactive oxygen species as intracellular messengers during cell growth and differentiation. *Cell Physiol Biochem* 11: 173–186, 2001.
118. Sawa A and Snyder SH. Schizophrenia: diverse approaches to a complex disease. *Science* 296: 692–695, 2002.
119. Schapira AH, Cooper JM, Dexter D, Clark JB, Jenner P, and Marsden CD. Mitochondrial complex I deficiency in Parkinson's disease. *J Neurochem* 54: 823–827, 1990.
120. Serrano F, Kolluri NS, Wientjes FB, Card JP and Klann E. NADPH oxidase immunoreactivity in the mouse brain. *Brain Res* 988: 193–188, 2003.
121. Siesjö BK. *Brain Energy Metabolism*. New York: Wiley, 1980, p. 131–150, 1980.
122. Seutin V, Scuvée-Moreau J, Masotte L, and Dresse A. Hydrogen peroxide hyperpolarizes rat CA1 pyramidal neurons by inducing an increase in potassium conductance. *Brain Res* 683: 275–278, 1995.
123. Shih JC, Chen K, and Ridd MJ. Monoamine oxidase: from genes to behavior. *Ann Rev Neurosci* 22: 197–217, 1999.
124. Slivka A, Mytilineou C, and Cohen G. Histochemical evaluation of glutathione in brain. *Brain Res* 409: 275–284, 1987.
125. Smith AD and Bolam JP. The neural network of the basal ganglia as revealed by the study of synaptic connections of identified neurons. *Trends Neurosci* 13: 259–265, 1990.
126. Sonsalla PK, Manzino L, Sinton CM, Liang CL, German DC, and Zeevalk GD. Inhibition of striatal energy metabolism produces cell loss in the ipsilateral substantia nigra. *Brain Research* 773: 223–226, 1997.
127. Starkov AA, Chinopoulos C, and Fiskum G. Mitochondrial calcium and oxidative stress as mediators of ischemic brain injury. *Cell Calcium* 36: 257–264, 2004.
128. Stone JR and Yang S. Hydrogen peroxide: a signaling messenger. *Antioxid Redox Signal* 8: 243–270, 2006.
129. Stults FH, Forstrom JW, Chiu, DTY, and Tappel AL. Rat liver glutathione peroxidase: purification and study of multiple forms. *Arch Biochem Biophys* 183: 490–497, 1977.
130. Tanaka J, Toki K, Zhang B, Ishihara K, Sakanaka M, and Maeda N. Astrocytes prevent neuronal death induced by reactive oxygen and nitrogen species. *Glia* 28: 85–96, 1999.
131. Tejada-Simon MV, Serrano F, Villasana LE, Kanterewicz BI, Wu GY, Quinn MT, and Klann E. Synaptic localization of a functional NADPH oxidase in the mouse hippocampus. *Mol Cell Neurosci* 29: 97–106, 2005.
132. Tokube K, Kiyosue T, and Arita M. Effects of hydroxyl radicals on K<sub>ATP</sub> channels in guinea-pig ventricular myocytes. *Pflügers Arch* 437: 155–157, 1998.
133. Tower DB and Elliott KAC. Activity of the acetylcholine system in cerebral cortex of various unanesthetized animals. *Am J Physiol* 168: 747–759, 1952.
134. Tower DB and Young OM. The activities of butyrylcholinesterase and carbonic anhydrase, the rate of anaerobic glycolysis, and the question of a constant density of glial cells in the cerebral cortices of various mammalian species from mouse to whale. *J Neurochem* 20: 269–278, 1973.
135. Trépanier G, Furling D, Puymirat J, and Mirault ME. Immunocytochemical localization of seleno-glutathione peroxidase in the adult mouse brain. *Neuroscience* 75: 231–243, 1996.
136. Tsukaguchi H, Tokui T, Mackenzie B, Berger UV, Chen XZ, Wang Y, Brubaker RF, and Hediger MA. A family of mammalian Na<sup>+</sup>-dependent L-ascorbic acid transporters. *Nature* 399: 70–75, 1999.
137. Votyakova TV and Reynolds IJ. ΔΨ<sub>m</sub>-Dependent and -independent production of reactive oxygen species by rat brain mitochondria. *J Neurochem* 79: 266–277, 2001.
138. Xia Y and Haddad GG. Major differences in CNS sulfonylurea receptor distribution between the rat (newborn, adult) and turtle. *J Comp Neurol* 314: 278–289, 1991.
139. Xu J, Kao SY, Lee FJ, Song W, Jin LW and Yankner BA. Dopamine-dependent neurotoxicity of α-synuclein: A mechanism for selective neurodegeneration in Parkinson disease. *Nature Medicine* 8: 600–606, 2002.
140. Yamada T, McGeer PL, Baimbridge KG, and McGeer EG. Relative sparing in Parkinson's disease of substantia nigra dopamine neurons containing calbindin-D28K. *Brain Res* 526: 303–307, 1990.
141. Yao JK, Reddy RD and van Kammen DP. Oxidative damage and



- schizophrenia: an overview of the evidence and its therapeutic implications. *CNS Drugs* 15: 287–310, 2001
142. Yu BP. Cellular defenses against damage from reactive oxygen species. *Physiol Rev* 74: 139–162, 1994.
143. Zekry D, Epperson TK, and Krause KH. A role for NOX NADPH oxidases in Alzheimer's disease and other types of dementia? *IUBMB Life* 55: 307–313, 2003.
144. Zhang Y, Dawson VL, and Dawson TM. Oxidative stress and genetics in the pathogenesis of Parkinson's disease. *Neurobiol Dis* 7: 240–250, 2000.
145. Zhou M, Diwu Z, Panchuk-Voloshina N, and Haugland RP. A stable nonfluorescent derivative of resorufin for the fluorometric determination of trace hydrogen peroxide: applications in detecting the activity of phagocyte NADPH oxidase and other oxidases. *Anal Biochem* 253: 162–168, 1997.

Address reprint requests to:

Dr. Margaret E. Rice  
Dept. of Physiology and Neuroscience  
NYU School of Medicine  
550 First Avenue  
New York, NY 10016

E-mail: margaret.rice@nyu.edu

Date of first submission to ARS Central, August 25, 2006; date of final revised submission, August 28, 2006; date of acceptance, September 10, 2006.



**This article has been cited by:**

1. Rinchen D. Lama, Karl Charlson, Arun Anantharam, Parastoo Hashemi. 2012. Ultrafast Detection and Quantification of Brain Signaling Molecules with Carbon Fiber Microelectrodes. *Analytical Chemistry* **84**:19, 8096-8101. [[CrossRef](#)]
2. Alexander R. Lippert, Genevieve C. Van de Bittner, Christopher J. Chang. 2011. Boronate Oxidation as a Bioorthogonal Reaction Approach for Studying the Chemistry of Hydrogen Peroxide in Living Systems. *Accounts of Chemical Research* **44**:9, 793-804. [[CrossRef](#)]
3. Jyoti C. Patel, Paul Witkovsky, William A. Coetzee, Margaret E. Rice. 2011. Subsecond regulation of striatal dopamine release by pre-synaptic KATP channels. *Journal of Neurochemistry* no-no. [[CrossRef](#)]
4. Sébastien Dilly, Jean-François Liégeois. 2011. Interaction of clozapine and its nitrenium ion with rat D2 dopamine receptors: in vitro binding and computational study. *Journal of Computer-Aided Molecular Design* **25**:2, 163-169. [[CrossRef](#)]
5. James G. Roberts, Keri L. Hamilton, Leslie A. Sombers. 2011. Comparison of electrode materials for the detection of rapid hydrogen peroxide fluctuations using background-subtracted fast scan cyclic voltammetry. *The Analyst* . [[CrossRef](#)]
6. D.B. Rosemberg, R.F. da Rocha, E.P. Rico, A. Zanutto-Filho, R.D. Dias, M.R. Bogo, C.D. Bonan, J.C.F. Moreira, F. Klamt, D.O. Souza. 2010. Taurine prevents enhancement of acetylcholinesterase activity induced by acute ethanol exposure and decreases the level of markers of oxidative stress in zebrafish brain. *Neuroscience* **171**:3, 683-692. [[CrossRef](#)]
7. Sabine D. Jordan, A. Christine Könnner, Jens C. Brüning. 2010. Sensing the fuels: glucose and lipid signaling in the CNS controlling energy homeostasis. *Cellular and Molecular Life Sciences* **67**:19, 3255-3273. [[CrossRef](#)]
8. Shiming Zhang, Hui Chen, Glenn S. Gerhard. 2010. Heme synthesis increases artemisinin-induced radical formation and cytotoxicity that can be suppressed by superoxide scavengers. *Chemico-Biological Interactions* **186**:1, 30-35. [[CrossRef](#)]
9. Carmen Sánchez-Lasheras, A. Christine Könnner, Jens C. Brüning. 2010. Integrative neurobiology of energy homeostasis-neurocircuits, signals and mediators. *Frontiers in Neuroendocrinology* **31**:1, 4-15. [[CrossRef](#)]
10. Peter S. Freestone, Kenny K. H. Chung, Ezia Guatteo, Nicola B. Mercuri, Louise F.B. Nicholson, Janusz Lipski. 2009. Acute action of rotenone on nigral dopaminergic neurons ### involvement of reactive oxygen species and disruption of Ca 2+ homeostasis. *European Journal of Neuroscience* **30**:10, 1849-1859. [[CrossRef](#)]
11. Guilherme Antônio Behr, Leonardo Lisboa da Motta, Marcos Roberto de Oliveira, Max William Soares Oliveira, Mariana Leivas Müller Hoff, Roberta Bristot Silvestrin, José Cláudio Fonseca Moreira. 2009. Decreased anxiety-like behavior and locomotor/exploratory activity, and modulation in hypothalamus, hippocampus, and frontal cortex redox profile in sexually receptive female rats after short-term exposure to male chemical cues. *Behavioural Brain Research* **199**:2, 263-270. [[CrossRef](#)]
12. X.-m. Zha, R. Wang, D. M. Collier, P. M. Snyder, J. A. Wemmie, M. J. Welsh. 2009. Oxidant regulated inter-subunit disulfide bond formation between ASIC1a subunits. *Proceedings of the National Academy of Sciences* **106**:9, 3573-3578. [[CrossRef](#)]
13. Zsuzsanna Sidló, Patricia H. Reggio, Margaret E. Rice. 2008. Inhibition of striatal dopamine release by CB1 receptor activation requires nonsynaptic communication involving GABA, H<sub>2</sub>O<sub>2</sub>, and KATP channels. *Neurochemistry International* **52**:1-2, 80-88. [[CrossRef](#)]
14. Jie Zeng, Gang Wang, Sheng-Di Chen. 2007. ATP-sensitive potassium channels: novel potential roles in Parkinson's disease. *Neuroscience Bulletin* **23**:6, 370-376. [[CrossRef](#)]
15. Katarzyna Kuter, Maria #mia#owska, Joanna Wiero#ska, Barbara Zi#ba, Jadwiga Wardas, Ma#gorzata Pietraszek, Przemys#aw Nowak, Izabela Biedka, Wojciech Roczniak, Jolanta Konieczny, Stanis#aw Wolfarth, Krystyna Ossowska. 2007. Toxic influence of subchronic paraquat administration on dopaminergic neurons in rats. *Brain Research* **1155**, 196-207. [[CrossRef](#)]
16. Dr. Ariel Kamsler , Menahem Segal . 2007. Control of Neuronal Plasticity by Reactive Oxygen Species. *Antioxidants & Redox Signaling* **9**:2, 165-167. [[Citation](#)] [[Full Text PDF](#)] [[Full Text PDF with Links](#)]